NANOPARTICLES & MICROPARTICLES TO COMBAT ANTIMICROBIAL RESISTANCE
Dr Anjana Jayasree,
Postdoctoral Research Fellow
School of Pharmacy and Pharmaceutical Sciences
The University of Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | December 2025
Dr Anjana Jayasree is an emerging research leader in biomaterials, tissue engineering and nanotechnology, recognised internationally for her innovative work on antimicrobial nanoparticles and regenerative therapies. A Postdoctoral Research Fellow at The University of Queensland, she operates at the intersection of materials science, drug delivery and cellular biology, developing advanced metallic-based nanotechnologies to improve both human and animal health outcomes. Her expertise spans nanoparticle synthesis, cell–material interactions, and the design of sophisticated in vitro models to investigate soft-tissue integration, osseointegration, angiogenesis and biofilm formation.
A central pillar of Dr Jayasree’s research is the engineering of next-generation metallic implants with precisely tailored surface modifications that enhance cellular attachment while simultaneously minimising bacterial colonisation and biofilm formation. By integrating bioactive ions, nanoscale architectures and smart antibacterial coatings, her work aims to accelerate healing, strengthen soft-tissue integration and significantly reduce implant-associated infection rates. This multidisciplinary program positions her at the forefront of innovation in regenerative dentistry and biomaterials-driven solutions to antimicrobial resistance.
Beyond her research, Dr Jayasree is a passionate advocate for STEM education and public engagement. She contributes to national outreach programs including Soapbox Science, the Kids STEM Convention and the Wonder of Science Young Science Ambassador initiative, inspiring the next generation of scientists through hands-on learning and accessible communication.
Driven, collaborative and highly creative, Dr Jayasree continues to advance impactful research that bridges fundamental science with real-world clinical and industry needs.
Source: Supplied
https://orcid.org/0000-0003-4719-0174
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
-
New treatments for patients with mental illness
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
